Advanced Search:
Equity Index

VVY.AS - VIVORYON

€0.81  -0.021 (-2.55%)

Updated: 08:04 May 9, 2024 EST

Next Session's AI Forecast

80.87%

Avg. Accuracy (AI)

€0.76

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€0.7

VIVORYON's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

VIVORYON - HISTORICAL DATA 6M

  • Last price

    €0.81

  • Daily change

    €-0.021

  • Previous Close

    €0.83

  • Last Updated

    08:04 May 9, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.04 3.02 0.03 0.19 -0.33

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
4.24 9.15 5.44 3.78 3.06

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
80% 92.39% 86.27% 4.41%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0.82 7.89% 0.76 26.67% 0.6 -89.4% 5.66

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.67 76.91 2.5 62.55

VIVORYON Technical Analysis News

VIVORYON

Weinbergweg 22
Halle 06120
Germany
49 345 555 9900
https://www.vivoryon.com

Sectors: Healthcare
Industry: Biotechnology
Description

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Corporate Governance

Vivoryon Therapeutics N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.